Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC:... Oncol Ther (2018) 6:45–58 https://doi.org/10.1007/s40487-018-0061-y ORIGINAL RESEARCH Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program . . . . Edgardo S. Santos Barry Kaplan Eli Kirshner Elisabeth F. Croft . . . Lecia V. Sequist MyDoanh Chau Jiefen Munley Geoffrey R. Oxnard Received: April 3, 2018 / Published online: May 25, 2018 The Author(s) 2018 and diagnostic methods used for T790M testing ABSTRACT in the EAP. Methods: Adult patients with EGFR T790M- Introduction: The osimertinib (AZD9291) US positive NSCLC following progression on prior Expanded Access Program (EAP) provided com- EGFR-TKI therapy (irrespective of line of ther- passionate access to osimertinib prior to US apy) were enrolled in the EAP and treated with Food and Drug Administration (FDA) approval 80 mg osimertinib once daily until dose reduc- for patients with advanced/metastatic epider- tion, discontinuation, or completion of the EAP mal growth factor receptor (EGFR) T790M-pos- following FDA approval (November 2015). Var- itive non-small cell lung cancer (NSCLC) ious testing methods were allowed for the following progression on tyrosine kinase inhi- required T790M testing. bitors (TKIs) targeting EGFR. Here, we report the Results: In total, 248 patients from 25 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/osimertinib-for-previously-treated-patients-with-advanced-egfr-t790m-wm00sdZmqg
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0061-y
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2018) 6:45–58 https://doi.org/10.1007/s40487-018-0061-y ORIGINAL RESEARCH Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program . . . . Edgardo S. Santos Barry Kaplan Eli Kirshner Elisabeth F. Croft . . . Lecia V. Sequist MyDoanh Chau Jiefen Munley Geoffrey R. Oxnard Received: April 3, 2018 / Published online: May 25, 2018 The Author(s) 2018 and diagnostic methods used for T790M testing ABSTRACT in the EAP. Methods: Adult patients with EGFR T790M- Introduction: The osimertinib (AZD9291) US positive NSCLC following progression on prior Expanded Access Program (EAP) provided com- EGFR-TKI therapy (irrespective of line of ther- passionate access to osimertinib prior to US apy) were enrolled in the EAP and treated with Food and Drug Administration (FDA) approval 80 mg osimertinib once daily until dose reduc- for patients with advanced/metastatic epider- tion, discontinuation, or completion of the EAP mal growth factor receptor (EGFR) T790M-pos- following FDA approval (November 2015). Var- itive non-small cell lung cancer (NSCLC) ious testing methods were allowed for the following progression on tyrosine kinase inhi- required T790M testing. bitors (TKIs) targeting EGFR. Here, we report the Results: In total, 248 patients from 25

Journal

Oncology and Therapy – Springer Journals

Published: May 25, 2018

References

  • Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival
    Brabender, J; Danenberg, KD; Metzger, R
  • Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer
    Liu, X; Wang, P; Zhang, C
  • Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung
    Rusch, V; Baselga, J; Cordon-Cardo, C
  • First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    Douillard, JY; Ostoros, G; Cobo, M
  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    Rosell, R; Carcereny, E; Gervais, R
  • First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Sequist, LV; Martins, RG; Spigel, D
  • Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
    Sequist, LV; Yang, JC; Yamamoto, N
  • Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
    Wu, YL; Zhou, C; Hu, CP
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
    Zhou, C; Wu, YL; Chen, G
  • Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Arcila, ME; Oxnard, GR; Nafa, K
  • Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Yu, HA; Arcila, ME; Rekhtman, N
  • Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation
    Oxnard, GR; Arcila, ME; Sima, CS
  • Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors
    Sun, JM; Ahn, MJ; Choi, YL
  • AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
    Janne, PA; Yang, JC; Kim, DW
  • AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
    Cross, DA; Ashton, SE; Ghiorghiu, S
  • Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor
    Finlay, MR; Anderton, M; Ashton, S
  • Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
    Yang, JC; Ahn, MJ; Kim, DW
  • Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
    Mok, TS; Wu, YL; Ahn, MJ
  • Osimertinib for pretreated EGFR Thr790 Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    Goss, G; Tsai, CM; Shepherd, FA
  • Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
    Soria, JC; Ohe, Y; Vansteenkiste, J
  • Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer
    Yoshioka, H; Komuta, K; Imamura, F
  • Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
    Zaarour, M; Weerasinghe, C; Nazha, B
  • The normal physiological changes of aging and their impact on the response to cancer treatment
    Blesch, KS
  • Osimertinib responses after disease progression in patients who had been receiving rociletinib
    Sequist, LV; Piotrowska, Z; Niederst, MJ
  • P3.02b-115 Clinical activity of osimertinib in EGFR mutation positive non-small cell lung cancer (NSCLC) patients (pts) previously treated with rociletinib
    Gadgeel, S; Chen, W; Piotrowska, Z
  • Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer
    Oxnard, GR; Thress, KS; Alden, RS
  • Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer
    Sacher, AG; Paweletz, C; Dahlberg, SE
  • 134O_PR: plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC)
    Jenkins, S; Yang, J; Ramalingam, S
  • ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study
    Reck, M; Hagiwara, K; Han, B
  • EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291
    Thress, KS; Brant, R; Carr, TH
  • Osimertinib for the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer
    Khozin, S; Weinstock, C; Blumenthal, GM
  • Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
    Dongiovanni, D; Daniele, L; Barone, C
  • Afatinib in non-small cell lung cancer harboring uncommon EGFR mutations pretreated with reversible EGFR inhibitors
    Heigener, DF; Schumann, C; Sebastian, M
  • Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
    Lee, VH; Leung, DK; Choy, TS
  • High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
    Perng, RP; Yang, CH; Chen, YM
  • Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib
    Schuler, M; Fischer, JR; Grohe, C